<DOC>
	<DOCNO>NCT02896218</DOCNO>
	<brief_summary>Vancomycin glycopeptide antibiotic first line antibiotic treatment serious gram-positive infection involve methicillin-resistant Staphylococcus aureus ( MRSA ) . Its therapeutic window narrow , need monitor serum vancomycin concentration clinical practice , especially critically ill patient . So far , study investigate clinical outcome dosage strategy vancomycin dosage administer adjust individually use PPK Bayesian method base observed concentration . The objective study investigate effectiveness , safety economics vancomycin individualized dosing service provide pharmacist .</brief_summary>
	<brief_title>Therapeutic Monitoring Vancomycin Critical Ill Patients : Registry</brief_title>
	<detailed_description>Vancomycin glycopeptide antibiotic first line antibiotic treatment serious gram-positive infection involve methicillin-resistant Staphylococcus aureus ( MRSA ) . Vancomycin use associate several adverse event , include nephrotoxicity ototoxicity . Its therapeutic window narrow , need monitor serum vancomycin concentration clinical practice , especially critically ill patient . Moreover , Chinese vancomycin TDM guideline recommend vancomycin dosage administer adjust individually base population pharmacokinetic ( PPK ) Bayesian method . However , gap clinical practice guideline . So far , study investigate clinical outcome dosage strategy vancomycin dosage administer adjust individually use PPK Bayesian method . Pharmacists could provide vancomycin individualized dosing service join ICU multidisciplinary team . The objective study investigate effectiveness , safety economics vancomycin individualized dosing service provide pharmacist . This single-center , ambispective cohort study . Patients retrospective prospective cohort divide 2 group exposure . The exposure whether patient receive pharmacist ' consultation . Patients meet inclusion exclusion criterion include registry . As non-intervention study , information collect : basic demographic , diagnosis , initial dosage regimen adjust strategy vancomycin , combine special treatment outcome .</detailed_description>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>Admitted intensive care unit ( ICU ) , Peking University Third Hospital since JAN 2010 . Receiving vancomycin therapy 72 hour . Aged â‰¥ 18 year . Administration vancomycin nonintravenous access . Life expectancy le 24 hour . Pregnancy woman . Presence immunodeficiency . Presence hematological disorder . Written inform consent obtain prospective cohort .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Vancomycin</keyword>
	<keyword>Critically Ill</keyword>
	<keyword>Pharmacist</keyword>
	<keyword>Population Pharmacokinetic</keyword>
	<keyword>Bayesian Methods</keyword>
</DOC>